最近身边有朋友在做美国的精油产品,名字是多特瑞,在全球都是直销模式,当然在中国已经有北京,上海和广

最近身边有朋友在做美国的精油产品,名字是多特瑞,在全球都是直销模式,当然在中国已经有北京,上海和广州都开有专卖店,但是有精油专家说精油本来是很慎重的,在法国,英国,不是医生不能随便给人开精油配方,尤其是口服精油,这种宣传方式有问题。多特瑞很多产品都能口服,她们自称她们的产品是CPTG的理疗产品,不知道有没有真正懂精油产品的资深人士,能否解答下像多特瑞这种宣传方式到底有没有问题,产品到底怎么样,精油严格来讲到底能不能做直销?

第1个回答  2021-04-03
多特瑞在中国不是直销,是传销
第2个回答  2020-06-02
我是一个美国人,我在中国工作的时候从中国朋友那里了解到多特瑞(dōTERRA)精油。关于多特瑞(dōTERRA)精油,在美国并不是家喻户晓的品牌,在精油世界也不是最大、唯一。它的特点在于非常规的营销模式,特别是不菲的激励使得代理们有很大积极性去推销。应该说多特瑞的宣传材料里的可能是个别的案例,但是不乏夸张的文字给人的感觉是置之四海皆通用。另外,回到美国比较了以下,这一家的价格的确偏高,在美国可信赖的连锁超市里的“有机农作物”专用货架/柜台,常年都有精油销售,同类且同计量的精油,价格好像差不多是多特瑞精油的1/3吧。当然,这很大原因也是因为多特瑞的营销不一样,他们不把产品推进超市,而是依靠群众,紧接地气,挖掘身边的客户,壮大客群。在美国,连锁超市为了确保运营持久,在产品的品质把关、检验、以及供应商的规范管理都很严格。也有些厂家就不走进超市这条路,而是直接依靠人民找群众。
几年前美国的FDA(美国食品药物管理局)就对多特瑞的总裁提出了警告并对公司罚款,精油并不是药品,也不在药品注册的名单框架内。多特瑞违反了《联邦法规》第21章第201.128条。 因为多特瑞的营销顾问(中国多叫做“老师”吧)把一些精油,如:“美乐家”,“牛至”,“守卫”,“丁香”,“桉树”,“乳香”,“天竺葵”,“薰衣草”,“柠檬草”,“没药”,“薄荷”,“迷迭香”,“冬青”,“快乐鼠尾草”和“香根草”等等,宣传说可以针对病毒感染(包括埃博拉病毒)、细菌感染、癌症、脑损伤、自闭症、子宫内膜异位症、格雷夫斯病、阿尔茨海默病、肿瘤减少、ADD/ADHD和其他疾病。
美国食品药物管理局严格禁令,要求精油制造商不得使用与疾病和治病相关的词语,比如cures(治愈)、treat(治疗)、therapeutic(类似于医治疗程)、repair(修复)等。
美国食品药物管理局之所以发出警告信,就是需要为药品负责,不希望不符合药品规则的产品,被市场营销误导,把它当作药品,那些顾问(中国多叫做“老师”)是工作很努力的,但是他们的利益与工作成果挂钩很紧密,有时候他们难免就会发力过猛去宣传(最后小声说一句“这不是药品” ,但是之前说的一万句的意思可能都被理解为“是比药品可能还好且没有副作用”),总之,使用者感觉像是治病的神器了。
以下是一封FDA给多特瑞的警示信件,我选摘自FDA的官方网站,里面有较为详细的提出,多特瑞的违规操作,供大家了解一下客观情况吧:https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/doterra-international-llc-09222014
***********
dōTERRA International, LLC
Attn: David Stirling
389 South 1300 West
Pleasant Grove, Utah 84062
Dear Mr. Stirling:
This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed websites and social media accounts (e.g. www.anytimeessentials.com, Facebook, Twitter, Pinterest, YouTube) used to promote your dōTERRA Essential Oil products in August 2014. Based on our review, FDA has determined that several of your dōTERRA Essential Oil products including, but not limited to, “Melaleuca,” “Oregano,” “On Guard,” “Clove,” “Eucalyptus,” “Frankincense,” “Geranium,” “Lavender,” “Lemongrass,” “Myrrh,” “Peppermint,” “Rosemary,” “Wintergreen,” “Clary Sage,” and “Vetiver” are promoted for conditions that cause them to be drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)]. The therapeutic claims establish that these products are drugs because they are intended for use in the cure, mitigation, treatment, or prevention of disease. The intended use of a product may be determined by, among other things, its labeling, advertising, and the circumstances surrounding its distribution, 21 C.F.R. § 201.128. As described below, the marketing of your dōTERRA Essential Oil products with drug claims and without FDA approved-applications is in violation the Act.
Your products are marketed through the website http://www.anytimeessentials.com/ and through paid "consultants," http://www.anytimeessentials.com/work-home/, otherwise referred to as "wellness advocates," http://www.mydoterra.com/. Your consultants promote your above mentioned dōTERRA Essential Oil products for conditions including, but not limited to, viral infections (including ebola), bacterial infections, cancer, brain injury, autism, endometriosis, Grave’s Disease, Alzheimer’s Disease, tumor reduction, ADD/ADHD, and other conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Moreover, your consultants redirect consumers to your website, www.doterra.com, to register as a customer or member (i.e., consultant), and to purchase your dōTERRA Essential Oil products.本回答被网友采纳
相似回答